INT205603

Context Info Confidence 0.16 First Reported 2007 Last Reported 2010 Negated 0 Speculated 0 Reported most in Body Documents 5 Total Number 5 Disease Relevance 4.84 Pain Relevance 0.15

extracellular space (Pdgfa) extracellular region (Pdgfa)

Anatomy Link Frequency platelet 2 mesenchymal cells 1 Pdgfa (Mus musculus)

Pain Link Frequency Relevance Heat fibrosis 101 97.00 antagonist 4 16.80 Arthritis 1 10.24 imagery 49 5.00 cytokine 22 5.00 Inflammation 18 5.00 positron emission tomography 14 5.00 Taxol 14 5.00 chemokine 8 5.00 Inflammatory response 5 5.00

Disease Link Frequency Relevance Heat Cancer 342 98.68 Pulmonary Fibrosis 68 97.00 Apoptosis 49 95.80 Fibrosis 58 93.32 Colon Cancer 6 93.32 Targeted Disruption 8 88.44 Hyperplasia 1 86.00 Hematologic Neoplasms 2 77.80 Death 5 76.88 Cicatrix 2 76.40

Sentences Mentioned In

Key:

Protein

Mutation

Event

Anatomy

Negation

Speculation

Pain term

Disease term

The effect of PDGF and VEGF receptor inhibitors on tumor vessel leakiness was determined by injection of Evans blue, a dye that quantitatively binds to albumin in the circulation.

Regulation (effect) of PDGF associated with cancer

1) Confidence 0.16 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2781164 Disease Relevance 1.07 Pain Relevance 0

Because PDGF is a key mitogen and chemoattractant for mesenchymal cells, targeting PDGF or its receptors could be effective in limiting the replication of these cells and reducing collagen deposition and matrix formation.

Regulation (targeting) of PDGF in mesenchymal cells

2) Confidence 0.14 Published 2010 Journal Fibrogenesis Tissue Repair Section Body Doc Link PMC2940818 Disease Relevance 0.93 Pain Relevance 0.15

The anti-tumor activity of SU6668 has been attributed to its antiangiogenic potential arising from its inhibitory effect on the receptor-tyrosine kinase activity of VEGF, FGF, and PDGF.

Regulation (effect) of PDGF associated with cancer

3) Confidence 0.13 Published 2007 Journal BMC Cancer Section Body Doc Link PMC1832206 Disease Relevance 1.98 Pain Relevance 0

Sunitinib and sorafenib are multitargeting TKIs that can block activity angiogenic targets such as of VEGFR1, 2, 3, platelet-derived growth factor (PDGF) receptors and c-Kit or RET.

Regulation (targets) of platelet-derived growth factor in platelet

4) Confidence 0.04 Published 2010 Journal Journal of Oncology Section Body Doc Link PMC2902148 Disease Relevance 0.43 Pain Relevance 0

Sunitinib and sorafenib are multitargeting TKIs that can block activity angiogenic targets such as of VEGFR1, 2, 3, platelet-derived growth factor (PDGF) receptors and c-Kit or RET.

Regulation (targets) of PDGF in platelet

5) Confidence 0.04 Published 2010 Journal Journal of Oncology Section Body Doc Link PMC2902148 Disease Relevance 0.43 Pain Relevance 0

General Comments

This test has worked.